Latest filings (excl ownership)
424B5
Prospectus supplement for primary offering
28 Jun 24
6-K
Leerink Partners LLC
28 Jun 24
6-K
Current report (foreign)
24 Jun 24
6-K
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5 Jun 24
6-K
Report of Foreign Private Issuer
21 May 24
6-K
Report of Foreign Private Issuer
8 May 24
6-K
Report of Foreign Private Issuer
25 Apr 24
6-K
Current report (foreign)
4 Apr 24
6-K
Corporate Presentation March 2024
21 Mar 24
20-F
2023 FY
Annual report (foreign)
21 Mar 24
6-K
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
21 Mar 24
6-K
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
25 Jan 24
6-K
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4 Jan 24
6-K
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
6 Nov 23
6-K
Current report (foreign)
1 Nov 23
6-K
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
11 Sep 23
6-K
Current report (foreign)
30 Aug 23
6-K
Report of Foreign Private Issuer
10 Aug 23
EFFECT
Notice of effectiveness
12 Jul 23
424B5
Prospectus supplement for primary offering
12 Jul 23
CORRESP
Correspondence with SEC
7 Jul 23
UPLOAD
Letter from SEC
6 Jul 23
F-3
Shelf registration (foreign)
30 Jun 23
6-K
InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
28 Jun 23
6-K
InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients
21 Jun 23
6-K
Current report (foreign)
11 May 23
6-K
Current report (foreign)
27 Apr 23
6-K
Current report (foreign)
13 Apr 23
424B5
Prospectus supplement for primary offering
13 Apr 23
424B5
Prospectus supplement for primary offering
11 Apr 23
6-K
Current report (foreign)
5 Apr 23
6-K
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
4 Apr 23
20-F
2022 FY
Annual report (foreign)
22 Mar 23
6-K
InflaRx Reports Full Year 2022 Financial and Operating Results
22 Mar 23
6-K
Current report (foreign)
5 Jan 23
6-K
Current report (foreign)
21 Dec 22
6-K
Current report (foreign)
9 Nov 22
6-K
Current report (foreign)
9 Nov 22
6-K
InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients
29 Sep 22
6-K
InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine
8 Sep 22
Latest ownership filings
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G
SUVRETTA CAPITAL MANAGEMENT, LLC
24 Apr 23
SC 13G
TANG CAPITAL PARTNERS LP
17 Apr 23
SC 13G/A
SUVRETTA CAPITAL MANAGEMENT, LLC
13 Feb 23
SC 13G/A
GREAT POINT PARTNERS LLC
14 Feb 22
SC 13G
SUVRETTA CAPITAL MANAGEMENT, LLC
8 Mar 21
SC 13G
GREAT POINT PARTNERS LLC
8 Mar 21
SC 13G/A
BAKER BROS. ADVISORS LP
16 Feb 21
SC 13D
Beneficial ownership report
18 Feb 20
SC 13D
InflaRx N.V.
18 Feb 20
SC 13G
Beneficial ownership report
14 Feb 20
SC 13G/A
InflaRx N.V.
14 Feb 20
SC 13G/A
InflaRx N.V.
14 Feb 20
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G/A
InflaRx N.V.
10 Jul 19
SC 13G/A
InflaRx N.V.
14 Jun 19
SC 13G/A
InflaRx N.V.
22 Apr 19
SC 13G/A
InflaRx N.V.
10 Apr 19
SC 13G/A
InflaRx N.V.
22 Mar 19
SC 13G/A
InflaRx N.V.
14 Feb 19
SC 13G/A
InflaRx N.V.
14 Feb 19
SC 13G/A
InflaRx N.V.
14 Feb 19
SC 13G
InflaRx N.V.
14 Feb 19
SC 13G/A
InflaRx N.V.
12 Feb 19
SC 13G/A
InflaRx N.V.
12 Feb 19
SC 13G/A
InflaRx N.V.
8 Feb 19
SC 13G/A
Beneficial ownership report (amended)
7 Dec 18
SC 13G/A
InflaRx N.V.
20 Nov 18
SC 13G/A
InflaRx N.V.
26 Apr 18
SC 13G
InflaRx N.V.
15 Feb 18
SC 13G
InflaRx N.V.
14 Feb 18
SC 13G
InflaRx N.V.
14 Feb 18
SC 13G
InflaRx N.V.
14 Feb 18
SC 13G
InflaRx N.V.
14 Feb 18
SC 13G
InflaRx N.V.
14 Feb 18
SC 13G
InflaRx N.V.
14 Feb 18
SC 13G
Beneficial ownership report
1 Feb 18
SC 13G
InflaRx N.V.
31 Jan 18
SC 13G
InflaRx N.V.
11 Dec 17
SC 13G
InflaRx N.V.
16 Nov 17